Evidence map›Paper›PMID 35235005›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2022

A self-triggered radioligand therapy agent for fluorescence imaging of the treatment response in prostate cancer.

Hongchuang Xu, Yanpu Wang, Jingming Zhang, Xiaojiang Duan, Ting Zhang, Xuekang Cai, Hyunsoo Ha, Youngjoo Byun, Yan Fan, Zhi Yang and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Hongchuang Xu *Department of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China.
Yanpu Wang *Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Jingming ZhangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China.
Xiaojiang DuanDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China.
Ting ZhangMedical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
Xuekang CaiDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China.
Hyunsoo HaCollege of Pharmacy, Korea University, 2511 Sejong-ro, Sejong, 30019, South Korea.
Youngjoo ByunCollege of Pharmacy, Korea University, 2511 Sejong-ro, Sejong, 30019, South Korea.
Yan FanDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China.
Zhi YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Yiguang WangState Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, China.
Zhaofei LiuMedical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China. liuzf@bjmu.edu.cn.
Xing YangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing, 100034, China. yangxing2017@bjmu.edu.cn.ORCID 0000-0001-5186-4990
Peking University · CNKorea University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) is emerging as an effective treatment option for metastatic castration-resistant prostate cancer (mCRPC). An imaging-based method to quantify early treatment responses can help to understand and optimize RLT.

methodsWe developed a self-triggered probe 2 targeting the colocalization of PSMA and caspase-3 for fluorescence imaging of RLT-induced apoptosis.

resultsThe probe binds to PSMA potently with a K

conclusionProbe 2 can potently bind to PSMA, and the fluorescence signal can be sensitively switched on by caspase-3 both in vitro and in vivo. This method may provide an effective tool to investigate and optimize PSMA-RLT.

Indexed as

LutetiumProstatic Neoplasms, Castration-ResistantAntigens, SurfaceCaspase 3DipeptidesGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingHumansMaleOptical ImagingTreatment OutcomeAntigens, SurfaceCaspase 3DipeptidesFOLH1 protein, humanGlutamate Carboxypeptidase IIHeterocyclic Compounds, 1-RingLutetiumCaspase-3Prostate cancerProstate-specific membrane antigen (PSMA)Radioligand therapySelf-triggered probe

Identifiers

PMID35235005
OpenAlexW4214910337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.